India, Aug. 17 -- Castle Biosciences, Inc. (CSTL), a diagnostics company developing innovative tests to guide patient care, announced that its common stock has been approved for a dual listing on Nasdaq Texas, while maintaining its primary listing on The Nasdaq Global Market under the ticker "CSTL."
Nasdaq Texas Listing
Castle announced today that it had received approval for a dual listing on Nasdaq Texas, while retaining its primary listing on The Nasdaq Global Market.
The additional listing is expected to enhance the company's visibility among investors and reflects Castle's Texas roots and strong connection to the state's growing life sciences and innovation ecosystem.
The dual listing will not affect Castle's business operations, r...